98%
921
2 minutes
20
Background: Time to bloodstream clearance is a critical prognostic indicator in various infections, yet limited data exist on the relationship between time to mycological clearance and outcomes in candidemia. This study aimed to assess the association between the duration of candidemia and outcomes in adult, hospitalized patients receiving empiric echinocandin treatment across U.S. hospitals.
Methods: A retrospective, multi-center study using the PINCI AI Healthcare Database (1/2016-4/2019) was conducted. Inclusion criteria: hospitalized adults (≥18 years) with Candida sp. identified on a clinical blood culture who received empiric echinocandin therapy (±2 days of index Candida sp. blood culture) for ≥ 3 days. Outcomes assessed were in-hospital mortality, length of stay (LOS), and hospital costs. The associations between increasing duration of candidemia relative to a single day of candidemia and outcomes were examined.
Results: A total of 867 patients met the criteria. Multivariable analysis showed that patients with candidemia lasting more than one day had significantly higher mortality, longer LOS, and higher hospital costs compared to those with only one day of candidemia. For each additional day of candidemia, the adjusted odds of in-hospital mortality increased by 3%, the adjusted median hospital length of stay post index collection day increased by 1.0 days, and the adjusted median total costs post index collection day increased by $3006.
Conclusion: Prolonged candidemia is associated with worse patient outcomes and higher healthcare costs. Further large-scale studies are needed to confirm these findings given the exploratory and observational nature of this study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/cid/ciaf472 | DOI Listing |
Curr Opin Crit Care
October 2025
Department of Health Sciences (DISSAL), University of Genoa.
Purpose Of Review: In candidemia, the standard 14-day antifungal treatment after blood culture clearance has been long accepted, despite being based on limited and outdated evidence. This review discusses the rationale for re-evaluating treatment duration, in the context of growing interest in optimizing antifungal use.
Recent Findings: A small number of retrospective studies have explored shorter treatment courses in uncomplicated candidemia, suggesting similar outcomes in terms of mortality and recurrence compared to the traditional 14-day regimen.
Clin Infect Dis
September 2025
OptiStatim, LLC, Longmeadow, MA, USA.
Background: Time to bloodstream clearance is a critical prognostic indicator in various infections, yet limited data exist on the relationship between time to mycological clearance and outcomes in candidemia. This study aimed to assess the association between the duration of candidemia and outcomes in adult, hospitalized patients receiving empiric echinocandin treatment across U.S.
View Article and Find Full Text PDFTher Adv Infect Dis
August 2025
Division of Infectious Diseases, Department of Medicine, Communicable Disease Centre, Hamad Medical Corporation, Doha, Qatar.
Background: Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before.
Objective: Compare efficacy and safety of anidulafungin versus caspofungin among patients with invasive candidiasis.
Curr Med Mycol
December 2024
Department of Pediatric Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey.
Background And Purpose: Today, with the development of critical patient care and the increase in intravascular invasive methods, the survival rate of patients diagnosed with hematological and solid organ malignancies is increasing, and unfortunately, the incidence of candidemia is also increasing due to multiple risk factors. In this study, we aimed to determine the clinical-demographic characteristics of candidemia and the antifungal susceptibility profile of in pediatric patients with hematological and solid organ malignancies.
Materials And Methods: The present study included pediatric patients with hematologic and solid organ malignancies presenting with signs and symptoms consistent with candidemia, in whom was isolated from blood and catheter cultures between January 2010 and August 2023.
Crit Care
July 2025
Laboratoire de Parasitologie-Mycologie, European Excellence Center in Medical Mycology (ECMM EC), Rennes University Hospital, Centre National de Référence Pour Les Mycoses Et Antifongiques LA-AspC Aspergilloses Chroniques, Rennes, 35000, France.
Background: Candidemia is a life-threatening fungal infection in intensive care unit (ICU) patients that can be complicated by secondary localization (SL). However, the prevalence, risk-factors, and outcomes of patients with secondary localization during candidemia remain poorly explored.
Methods: The CandidICU study was a retrospective multicenter cohort study conducted in 16 French ICUs.